Monthly Archives: August 2021

The Bat Elixir: Geneticists Suspect that the Flying Mammal Holds the Key to Extended Healthy Life | The Weather Channel – Articles from The Weather…

Posted: August 31, 2021 at 1:58 am

A bat in flight.

Bats have developed a pretty bad rap sheet in the last few years. First, pop culture painted these mammals as a form of the blood-sucking Dracula, and then they were villainised for allegedly triggering a pandemic. Indeed, these poor creatures can't seem to catch a break! Aside from being adorable, bats have several other redeeming qualities like being the only mammals capable of flying and finding food even in complete darkness.

Of late, experts in genetics have uncovered a few startling facts about these Chiropterans, which could imply that they may hold the secret to healthy ageing. With the COVID-19 pandemic turning the spotlight on bats, their unique ability to stay alive against unmatched odds has also come under scrutiny.

The relationship between the size of a mammal, its metabolism, and lifespan is relatively straightforward. The larger the mammal, the slower its metabolism is, and this means a longer lifespan. While we humans ourselves are an exception to this rule, these flying mammals also deviate from this trend.

Some bats are known to live for 40 yearsthat's eight times longer than the lifespan of other animals their size! This unusually long lifespan of bats has always aroused the curiosity of scientistsit prompted them to ask the question, what was it that made these bats live longer?

The gene expression pattern in bats is very unique and has been associated with DNA repair, autophagy, immunity and tumour suppression, ensuring an extended health span for bats. Now, scientists are wondering if we could replicate a few such attributes on humans as well!

There's a cap-like structure called the telomere present at the end of each chromosomea microscopic threadlike part of the cell that carries part or all of the genetic material. This unique structure protects your chromosomes from damage. Every time your cells replicate, the chromosome loses just a little bit of the telomere. As time passes, this telomere gets very short, and either rides the wave of ageing or causes the cell to self-destruct. To put it succinctly, the shortening of your telomeres is why you age.

While this seems inevitable, studies conducted in the last few years revealed that the telomeres do not shorten in long-lived species of batslike the Myotis genus. This means that these species can protect their DNA for an unusually long-time in their lifespan.

A bat pup.

It's common knowledge that in humans, the body's ability to heal and repair any damage decreases considerably as we age. But researchers studied the genome of young, middle-aged, and old bats and found that their ability to repair DNA and damage caused by age increased as they grew older.

Another quality that contributes to their longevity is their ability to control their immune responses. With an over-excited immune response, humans tend to succumb to infections like COVID-19 quicker. In COVID-19 patients with regulated immune responses, the risk of ending up on the ventilator is much lower, reveals research.

Similarly, a controlled immune response could be why bats are able to carry numerous deadly pathogens like the coronavirus without succumbing to them easily.

Humans and bats have many similar genes but with a tweak here and a nip there. So, if we could someday discover what factors elicit these controlled immune responses and telomere shortening avoidance in bats and replicate it in humans, it would be a massive leap towards the utopian dream of a healthy, long life!

For weather, science, and COVID-19 updates on the go, download The Weather Channel App (on Android and iOS store). It's free!

Posted in Genetics | Comments Off

Roslin Tech in multi-million bid to fund sustainable food – HeraldScotland

Posted: August 31, 2021 at 1:56 am

Roslin Technologies, which is advancing research to build better sustainability into the global food chain, is gearing up for a multi-million-pound fundraising following the June appointment of new chief executive Ernst van Orsouw.

The Series A investment round is due to launch in late September or early October, and follows an initial 10 million cash injection in 2017. The business was founded in that year as a joint venture between investment manager Milltrust International, JB Equity and the University of Edinburgh, all of whom are current shareholders.

The money will fuel the firms transition from research to commercialisation of its leading technology in the field of cultivated meat genuine animal flesh that is produced in a laboratory, eliminating the need to raise and slaughter animals. Roslin Techs role in this is to provide the iPS cells (induced pluripotent animal stem cells) that can replicate forever into any type of tissue desired.

Our cells are market-ready," Mr van Orsouw said. We have developed them to a stage where cultivated meat producers can put them into their processes.

A tri-lingual speaker, Mr van Orsouw earned a degree in electrical engineering from Delft University before joining the Royal Netherlands Navy working as a technical coordinator in shipbuilding. After a year he joined Shell as a petrophysicist, where he worked on the exploration and production of oil and gas reserves in the North Sea.

READ MORE:New chief for 'jewel in the crown' of AgTech

However, he soon realised that he was not suited to the industry, which did not align with his sustainable values. He also wanted to pursue work where his efforts would come to quicker fruition.

In the oil industry in general, you work to very long timelines, he said. I personally had a desire to make more of an impact earlier on.

In 2005 he joined the Amsterdam office of the Boston Consulting Group (BCG), the US management consulting firm that is the worlds second-largest in terms of revenue. There he focused on the agribusiness sector, a job which took him to both New York and San Francisco.

During his time at BCG he worked with UK-headquartered Genus, whose genetic products are used by cattle and pig farmers to reduce disease and boost production. In 2015 he joined the Pig Improvement Company (PIC), Genus porcine subsidiary, as director of strategy and marketing based in Tennessee.

During his time at PIC, Mr van Orsouw led a series of initiatives and acquisitions across the animal breeding and genetics sectors. When approached about the possibility of taking over at Roslin Tech which has preferential access to intellectual property from the Roslin Institute, the home of Dolly the Sheep the lure of working alongside such an esteemed group was too powerful to resist.

READ MORE:Roslin Technologies make breakthroughs in cellular technologies

It [the Roslin Institute] is probably the most famous biotech institute in the world, so clearly that interested me, he said. Roslin Technologies is unique. We have a small team of about 20 incredibly gifted people, and through that private relationship with the Roslin Institute, we are backed up by hundreds of some of the best people in the world in this field.

Mr van Orsouw took over at Roslin Tech from executive director and founder Glen Illing, who also has links to JB Equity. His predecessor, whom Mr van Orsouw describes as an incredible visionary, continues with Roslin Tech as the point man on potential acquisitions and is also in charge of its Insect Nucleus Facility near its headquarter in Midlothian.

Roslin Tech announced last year that it would build the 500,000 facility following its investment in Protenga, a Singapore firm that farms black soldier flies. Dubbed the superstars of sustainability, the larvae of these insects are edible and rich in nutrients.

Used for animal feed and fertiliser, insect protein competes in this market with cheaper but less reliable supplies of fish meal. Mr van Orsouw said Roslin Tech expects to get its first breeding lines out into the market next year.

What is most exciting about what we do is that we have these two main areas, and both are incredibly novel, he said. The positive impact they can have is incredible.

READ MORE:Roslin Technologies invests in superstar insects of sustainable food

While insect protein currently runs at two to three times the cost of fish meal, Mr van Orsouw said cultivated meat costs anything between 50 and 2,000 times its traditional counterpart to produce. The challenge for Roslin Tech is to optimise its iPS cells to bring down the expense.

It is therefore a nascent segment in the $1 trillion (727 billion) global livestock market, but is attracting increasing interest after Singapore in 2020 became the first country to approve East Justs flagship cultured chicken nuggets for sale nationwide. Roslin Tech has also made its own chicken nuggets in the lab, but these are not for commercial distribution.

Mr van Orsouw said the fresh funding will help Roslin Tech further develop both the cultivated meat and insect protein sectors faster than would otherwise be the case: We have incredibly ambitious plans for growth. Scotland will always be our headquarters but we want to open international bases as well. Technical acquisitions could be a part of that.

What countries have you most enjoyed travelling to, for business or leisure, and why?

Mozambique (leisure) and China (business & leisure). Both countries have tremendous natural beauty, great cultures, and incredible people but lack availability of affordable, sustainably produced proteins. It is a privilege to work on solutions that can help increase the local availability of affordable, nutritious and responsibly produced animal proteins.

When you were a child, what was your ideal job? Why did it appeal?

I had always wanted to do something with physics or biology. As a child I was curious to understand how nature works. Now I enjoy the challenge of how to turn the understanding of natures building blocks into a meaningful contribution to society.

What was your biggest break in business?

During my time in the United States, I was one of the initiators of the Coalition for Responsible Use of Gene editing in Agriculture, a food system-wide group that included a wide variety of players aiming to build consumer trust and confidence in gene editing techniques. It was incredibly rewarding to work with such a diverse group to identify ways to introduce new technologies that align with the values of consumers.

What was your worst moment in business?

During my work in the livestock industry, I have encountered several situations where we had to manage devastating disease outbreaks. It is very tough to experience the impact that these diseases have on the animals, the farmers and their families.

Who do you most admire and why?

I seek to work with people that are intrinsically curious, have a passion, that have the patience to pursue that passion, and can motivate others. I have been lucky enough to have had colleagues and supervisors, both current and past, that fit that description and that I have learned from.

What book are you reading and what music are you listening to?

I am reading The Wizard and the Prophet, Two Remarkable Scientists and Their Dueling Visions to Shape Tomorrows World by Charles Mann, a brilliant book that helps understand the motivations behind people in industrial agriculture as well as the environmental movement. On the bus to work I often listen to Congolese Soukous.

Read the original:
Roslin Tech in multi-million bid to fund sustainable food - HeraldScotland

Posted in Tennessee Stem Cells | Comments Off

25 Fad Diets That Did Not Stand the Test of Time – Parade Magazine

Posted: August 31, 2021 at 1:54 am

For almost as long as people have been eating food, dietsor at the very least, specific methods of eatinghave been popular. Women especially fall on the receiving end of many cultural expectations about weight and shape. While supple curves were once considered a highly-desired trait, thought to be significant of fertility and riches, the last two hundred years have seen a decided preference for slim and trim body types.

For every sensible eater who counts calories and exercises more, there are a dozen who want to lose weight quickly and are willing to go to extremes to achieve that goal. Below are the most dangerous, previously trendy or just overall goofy fad diets of modern history. Let many serve as a warning that, if it sounds too good to be true, it probably is.

Related: 30 Habits Healthy People Live By

Perhaps the most notorious fad diet is also the oldest. With no known date of origin, people in search of weight lossand especially womenhave made jokes about swallowing tapeworm eggs for over two hundred years. While this parasite, which takes up residence in the hosts intestines, may indeed lead to rapid weight loss, it can also cause organ failure and even death. Luckily, the actual use of the tapeworm diet today seems to be mostly anecdotal. Though that doesnt keep the kids from mentioning it on TikTok, however!

Created by fundamentalist minister Sylvester Graham, the eponymous diet consisted of mainly overcooked vegetables with no spices or dressings. Flour-based baked goods were verboten, as were salt, pepper and butter. According to Graham, the more enjoyable food was, the more likely it was to overexcite the digestive organs. In an age where cholera was running unchecked with no known cause, Grahams claims to health were viral. Graham was also concerned with minimizing sexual lust and deviance, and his very bland diet would supposedly fit the bill.

Horace Fletcher, a nutritionist with no formal education, rocked America with his diet idea to chew every bite of food 100 times to lessen hunger and save money on groceries every month. It is a known fact that people who eat slowly gain less weight, and studies have shown that chewing up to 35 times per mouthful can lower food consumption by 12%. Even so, all that excessive chewing was just thatexcessive.

Before the public associated cigarettes with lung cancer, heart disease and bad breath, smoking was considered rather glamorous. Ads for Lucky Strike cigarettes in the 1920s urged women to Reach for a Lucky instead of a sweet. Basically, instead of putting something yummy in your mouth, youd smoke a cigarette instead. While smoking cessation is associated with weight gain, doctors do not recommend nicotine as a weight-loss drug nowadays due to its many negative side effects.

The Hollywood Diet was probably the first celebrity-endorsed weight loss plan. Based on the (mistaken) belief that grapefruit had excellent fat-burning properties, adherents would eat half a grapefruit three times a day before every meal. Although it now may sound like the height of silliness, sex symbol Marilyn Monroe swore that the diet kept her waist trimperhaps because grapefruit is still a nutritious choice as part of a healthy diet.

Related: The 5 Best Diets to Help Manage Your Weight After 50

Surely youve heard about how Beyonce got into perfect shape for Dreamgirls by gulping a concoction of hot water, lemon juice, cayenne pepper and maple syrup? This diet, which has had staying power, began in the 1940s when Stanley Burroughs came up with what he called The Master Cleanse. Obviously, any kind of liquid- or partial-liquid diet will make you drop pounds (temporarily)but with few calories and almost no nutritional value, many health experts would argue that this diet is unsafe.

Like so many deceptive fad diets over the years, this very particular diet lured women in with the premise that they could eat as much as they wanted as long as they consumed nothing but cabbage soup. At least three bowls of cabbage soup were to be consumed daily on this diet, although some variations allowed for the addition of lean poultry. People did lose weight on this regime, but excessive flatulence was a significant problem for participants.

Nowadays, you might grab a SlimFast if you want a meal replacement shake. In 1961, however, there was Sego: a compound made of baby formula mixed with different flavors like chocolate malt, vanilla and banana. Advertisements bragged that Sego shakes could help dieters through the Temptation Hours. At only 225 calories a pop, its understandable why this once trendy diet did not last long.

Helen Gurley Brown, the eventual editor of Cosmo, touted a diet that would make women feel sexy and young. It consisted of an egg apiece for breakfast and lunch, washed down with black coffee and a glass of white wine. Dinner was a steak and what was left of the bottle of wine. Lacking many necessary nutrients, this fad diet was left in the 60s.

Related: Thinking About Going Low-Carb? Here Are 6 Diets to Choose From

While most fad diets are aimed squarely at women, this one targeted men looking to slim down and up their macho quotient. Ideally, participants would consume manly proteins like steak and lobster, along with large amounts of booze. It was, if you squinted right, a predecessor of modern low-carb diets.

It sounds like the ultimate dieting hack: If youre sleeping you cant be hungry, right? It made sense to medical doctors in the 70sthe height of diet pill maniawho prescribed handfuls of sedatives to homemakers so that they could sleep off their cravings. Elvis was a fan of this form of weight loss, which is no longer practiced.

Who doesnt love cookies? That was the basis of a creative diet plan by Dr. Sanford Siegal, who concocted prescription-only low-fat cookies that claimed to have a proprietary hunger controlling formula. The cookies were costly ($179.99 for a months supply), and participants were limited to just 500-700 calories of other food per day. While people successfully lost weight and this calorie-restrictive fad diet is still around, the calorie intake falls below most accepted recommendations for healthy weight loss and has understandably waned in popularity.

Dr. Herman Tarnower of Scarsdale, NY, created a sensation with the Scarsdale Diet in the late 1970sthe heyday of the fad diet. Tarnowers plan suggested a minimal calorie consumption for all dieters, regardless of sex, size or age, along with a diet rich in protein that also eliminates many healthy foods like nuts, avocado, sweet potatoes and whole grains. It was meant to be followed for two weeks at a time, which also encouraged yo-yo dieting.

This diet, which consists of eating nothing but fruit for 42 days (an updated version of the diet recommends 35 days), has been referred to as among the most dangerous plans of all time due to the inevitable loss of lean body mass and potassium. It also negatively impacted participants blood sugar. The new version of this diet is similarly considered a fad diet that unnecessarily restricts calories.

Consume a few of these delicious treats, and enjoy a marked decrease in hunger! The Ayds candies actually developed quite a following, but due to their unfortunate name, they fell off the market amidst the AIDS crisis of the 1980s.

Related: What Is the Optavia Diet and What Can You Eat on It?

Oprah endorsed this diet plan, also called the Optifast Plan, in which dieters consumed no solid food. Just specific (and expensive) shakes were ingested. Oprah claimed that she lost 67 pounds on this planevery one of which she gained back, plus some, as soon as she started eating regular food again (which she attributes to her metabolism being shot by the end). Unfortunately, this story of rapid weight loss and subsequent weight gain was ubiquitous among liquid dieters, and this fad did not last long.

Hating on fat was faddish in the diet industry at the end of the last century. Low-fat food like SnackWells cookies was all the rage. However, what people didnt realize was that fat wasnt the enemy, especially when low fat foods were stuffed full of added sugars to make them taste better. Mark this one up to a massive misunderstanding about the way that weight loss works.

Could your blood type influence how you digest food and what nutrients you need? Peter DAdamo, a naturopath, thought so. The idea was that certain foods contained lectins that conflicted with a persons blood type, causing inflammation and even cancer. For example, people with Type O blood were said to digest meat well, while other types werent. Unfortunately, there was no actual medical validity to these claims. Also, the typed diets were each missing crucial nutrients.

Who can forget Jared Fogel, who rose to fame with his claims of losing 245 pounds by eating two meals a day at Subway? Although the sandwich chain embraced Fogel, placing cardboard stand-ups of him in lobbies and using him to promote their healthier offerings, Subway claims that they never endorsed their eponymous diet and encouraged customers to eat balanced meals.

Celebs like Jennifer Aniston swore by this once trendy diet, in which participants ate about fourteen jars of baby food a day. Since there is an extreme calorie deficit, this diet definitely causes weight loss. However, since baby food nutrition is formulated for infants and not for adults, it also causes nutritional deficits.

Raw foodists claim that food loses life force when cooked. As the diet name suggests, raw foodists espouse eating nothing but raw whole foods. Not only is this diet incredibly restrictive, but it also has no bearing in actual science.

Related: New Research Finds That the Mediterranean Diet May Protect Against Alzheimers

Folks who have undergone fertility treatments are familiar with hCG, human chorionic gonadotropin. It can help a pregnancy stick, but a few years ago, people would inject themselves with a daily shot of this hormone and consume 500-800 calories a day. Not only were the calorie goals overly restrictive, leading to malnutrition, but the FDA eventually banned hCG for weight loss, citing a number of negative side effects.

Another fad diet that didnt last long, the Five-Bite diet was actually endorsed by a physicianDr. Alwin Lewis, of Burbank, California. The diet is simple: You can eat anything you want, but only five bites of it at lunch and another five at dinner. No breakfast. This diet leads to a massive, unhealthy and unsustainable calorie deficit for participants. As with any diets recommending limited intake of nutritious foods and severe calorie restriction, this is diet does not stand up to scientific studyand often leads to weight regain.

A concerning lifestyle trend, this diet espouses consuming nothing but sunlight, fresh air and, for some, tea. Breatharians have died from this fad diet, and no medical doctors and mainstream sources recommend this form of dieting. While intermittent fasting does have science to back it up, abstaining from all food and water does not.

Astoundingly dangerous, the Cotton Ball diet was one of the first fad dieting trends popularized by social media. Participants dipped up to five cotton balls in a juice of their choice and then consumed them in the hopes of making their stomachs feel full. Since cotton balls are not meant to be eaten, this diet has had dire consequences, including bowel obstruction.

Get good vibes and health tips delivered right to your inbox!

As you can see, fad diets are far from a thing of the past. With the prevalence of social media, it is actually easier than ever to be influenced into diets backed by little scientific evidence. Luckily, the internet has a silver lining: It is easier than ever to research types of diets and find the eating plan that can help you reach your happy weight!

Next up, Are We Finally Starting to See The End of Dieting Culture?

Follow this link:
25 Fad Diets That Did Not Stand the Test of Time - Parade Magazine

Posted in HCG Diet | Comments Off

Scope of Endocrine Testing Market Size, Status and Top Key Vendors (Abbott, Agilent, Bio Rad, Roche, Quest Diagnostics, QIAGEN) | Forecast to 2028 …

Posted: August 31, 2021 at 1:54 am

Global Endocrine Testing Market Synopsis:

An excellent Endocrine Testing marketing report is a well-known source of information that presents a telescopic view of the current market trends, situations, opportunities and status. The market analysis report focuses on global leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out in this business document. The geometric data brought together to generate Endocrine Testing report is mostly denoted with the graphs, tables and charts which make this report more user-friendly.

The Global Endocrine Testing Market to account from USD 9,067.33 Million in 2020 to USD 14,321.57 Million by 2028 growing at a CAGR of 5.88% in the forecast period of 2021 to 2028.

Available Exclusive Sample Copy of this Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-endocrine-testing-market .

According to the market report analysis, endocrine system basically comprises of the endocrine glands such as the pituitary, thyroid, pancreas, adrenal among others. The endocrine testing is basically conducted to find out the levels of various hormones, check function of endocrine glands, cause of an endocrinological problem or an earlier diagnosis.

The major key factors driving the growth of the Global Endocrine Testing Market are growing prevalence of endocrine disorders and other diseases such as obesity, diabetes, thyroid disease and others, sedentary lifestyle, unhealthy diet and increasing aged population. In addition, the high cost of advanced endocrine testing products might restrain the overall growth of the market. The heavy investment and advancements in product technologies is estimated to generate new opportunities within the forecast period.

Geographically, an influential Endocrine Testing marketing report is categorized into various regions, including sales, proceeds, market share and expansion rate (percent) in the following areas, North America, Asia-Pacific, South America, Europe, Asia-Pacific, The Middle East and Africa. What is more, the feasibility of new investment projects are assessed and overall research conclusions offered. Moreover, Endocrine Testing report gives idea to the clients about the market drivers and restraints with the help of SWOT analysis and also provides all the CAGR projections for the historic year 2019, base year 2020, and forecast period of 2021-2028.

Access Complete Report @ https://www.databridgemarketresearch.com/reports/global-endocrine-testing-market .

Global Key Players:

1 Abbott

2 DH Tech. Dev. Pte. Ltd

3 Biomedical Technologies Limited

4 Agilent

5 Beckman Coulter, Inc

6 bioMrieux SA

7 Bio Rad Laboratories Inc

8 DiaSorin

9 F. Hoffmann-La Roche Ltd

10 Laboratory Corporation of America Holdings

11 Quest Diagnostics Incorporated

12 Hologic, Inc

13 Ortho Clinical Diagnostics

14 QIAGEN

15 American Chemistry Council, Inc

Global Endocrine Testing Market Segmentation:

Test Segmentation:

1 Thyroid Test2 Insulin Test3 Dehydroepiandrosterone Sulfate (DHEAS)4 Human Chorionic Gonadotropin Test5 Human Chorionic Honadotropin (HCG)6 Follicle Stimulating (FSH)7 Prolactin Test8 Luteinizing Hormone9 Progesterone Test10 Others

Technology Segmentation:

1 Immunoassay2 Monoclonal and Polyclonal Antibody Technologies3 Clinical Chemistry Technologies4 Tandem Mass Spectroscopy5 Sensor Technology6 Others

End-User Segmentation:

1 Hospitals2 Clinical Laboratories3 Others

Get a TOC of Global Endocrine Testing Market Report 2021 @ https://www.databridgemarketresearch.com/toc/?dbmr=global-endocrine-testing-market .

Report contents include

1 Analysis of the Endocrine Testing Market including revenues, future growth, market outlook2 Historical data and forecast3 Regional analysis including growth estimates4 Analyses the end user markets including growth estimates5 Profiles on Endocrine Testing including products, sales/revenues, and market position6 Endocrine Testing Market structure, market drivers and restraints

Get Our More Trending Research Report Here:

1 Multiple Endocrine Neoplasia Treatment Market (Global Multiple Endocrine Neoplasia Treatment Market Industry Trends and Forecast to 2028)

2 Endocrine Disorders Market (Global Endocrine Disorders Market Industry Trends and Forecast to 2027)

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: Corporatesales@databridgemarketresearch.com

Posted in HCG Diet | Comments Off

BioCure Technology to Develop ROR1-Targeted CAR-T Cell Therapy – Precision Oncology News

Posted: August 31, 2021 at 1:49 am

NEW YORK BioCure Technology on Monday said it will begin developing a CAR T-cell therapy for chronic lymphocytic leukemia, or CLL,and solid tumors and seek to patent a novel ROR1-targeted CAR T-cell platform.

For several years, BiocurePharm, a subsidiary of the Vancouver-based BioCure Technology, has been advancing CD19-directed CAR T-cell therapies for acute lymphocytic leukemia, or ALL. In December 2020, BioCure announced plans for a Phase I study of its CD19 CAR T-cell therapy in ALL in South Korea and submitted an investigational new drug application to the Korean Ministry of Food and Drug Safety for that study. The company also has several partnerships to study the CD-19 CAR T-cell therapy including one with Pharos Vaccineto evaluate it for leukemia and lymphoma and another deal to study it in combination with Y Biologics' checkpoint inhibitor in solid tumors.

Based on that experience, BioCure has now decided to advance a novel ROR1 CAR T-cell therapy combined with a double specific antibody for CLL and solid tumors, such as ovarian and lung cancers. The decision was driven by the larger market opportunity presented by CLL compared to ALL and the fact that the CLL CAR T-cell therapy market is less crowded than the CD-19 targeted therapy space, the company said in a statement.

BioCure believes that pursing development of its CAR T-cell therapy in the less competitive CLL space will also increase its chances for obtaining patents protecting its ROR1 CAR T-cell therapy platform.

"The company is extremely excited to be focusing its work in the CAR T-cell cancer therapy field targeting CLL and solid tumors, having spent more than three years to arrive at this stage as a result of its previous work in the CD-19 CAR T and biosimilars space," BioCure CEO Sang Mok Lee said in a statement. "With the company developing its own CAR T technologies protected by patents, the company looks forward to driving strong returns for all of its shareholders in the rapidly growing market of CAR T-cell cancer therapy."

Read the original here:
BioCure Technology to Develop ROR1-Targeted CAR-T Cell Therapy - Precision Oncology News

Posted in Cell Therapy | Comments Off

A Phase I Study of FT819 CAR T-Cell Therapy in People with B-Cell Cancers – On Cancer – Memorial Sloan Kettering

Posted: August 31, 2021 at 1:49 am

Full TitleA Phase I Study of FT819 in Subjects with B-cell MalignanciesPurpose

The purpose of this study is to find the best way to give the investigational therapy FT819 safely in patients with B-cell lymphoma (BCL), chronic lymphocytic leukemia (CLL), or B-cell acute lymphocytic leukemia (B-ALL) that came back or continued to grow despite prior treatment.

FT819 is a cellular immunotherapy made in a laboratory starting with white blood cells (called T cells) that come from a healthy donor. The donated T cells are genetically modified to help them identify and kill cancer cells. A protein called chimeric antigen receptor (CAR) is added to the FT819 cells. CAR recognizes a protein called CD19 which is found on B-cell cancer cells. FT819 binds to B-cell cancer cells that contain CD19 and kills them. This CAR T-cell therapy is given intravenously (by vein).

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

For more information about this study and to inquire about eligibility, please contact Dr. Jae Park at 646-608-3743.

Read the original:
A Phase I Study of FT819 CAR T-Cell Therapy in People with B-Cell Cancers - On Cancer - Memorial Sloan Kettering

Posted in Cell Therapy | Comments Off

Cell Therapy Packaging Products and Services Market by Type – GlobeNewswire

Posted: August 31, 2021 at 1:49 am

New York, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cell Therapy Packaging Products and Services Market by Type of Therapy, Package Engineering Design, Scale of Operation and Geography : Industry Trends and Global Forecasts, 2021-2030" - https://www.reportlinker.com/p06130493/?utm_source=GNW Presently, more than 30 cell-based therapy products have received marketing approvals across various geographies, while more than 1,000 therapeutic candidates are under clinical evaluation. Considering the lucrative investment opportunity within this domain, several investors are actively supporting ongoing / future product development programs in this upcoming field of pharmacological interventions. In fact, there has been a 240% increase in investment activity, in terms of capital amount invested, between 2019 and 2020. However, the ultimate success of cell therapies is dependent on the safe and timely delivery of viable doses of therapeutic cells to the right patient. In this context, it is worth highlighting that drug product manufacturing, packaging and logistics operations involving cell therapies are both complex and challenging. Moreover, in order to ensure the stability of such products across the supply chain, specific temperature conditions (cryogenic, ambient or refrigerated) are required, in addition to specialized packaging material. Considering that most cell therapies are personalized, it is imperative that errors in labeling are avoided at all costs.

Given the need for costly and specialized equipment and the complexities associated with handling cell-based therapy products, innovators in the healthcare industry are likely to involve contract service providers for their drug product production, packaging and transportation requirements. Over time, regulators across the world, including the US Food and Drug Administration (FDA) and the International Air Transport Association (IATA), have established guidelines for the packaging, storage and transport of cell therapies. Since CMOs / CDMOs with the necessary capabilities to handle cell therapies are also likely to have established processes that comply with the current acceptable standards across different global regions, it is better for therapy developers to strategically partner with the aforementioned players instead of focusing on developing in-house capabilities. Presently, close to 60 companies claim to be offering cell therapy packaging services and associated products. In fact, it is estimated that close to 30% of drug substance and drug product related operations of advanced therapy medicinal products are already outsourced to capable CMOs / CDMOs. Further, over the last few years, several service providers have also forged strategic alliances among themselves, in order to further expand existing capabilities and augment their respective service offerings. Given the rising trend of outsourcing in the healthcare industry, and the ongoing efforts of service providers to further improve their portfolios, we believe that the cell therapy packaging products and services market is likely to evolve at a steady pace in the next few years.

SCOPE OF THE REPORT The Cell Therapy Packaging Products and Services Market by Type of Therapy (T-cell Therapies, Dendritic Cell Vaccines, Stem Cell Therapies, NK Cell Therapies and Other ATMPs), Package Engineering Design (Primary and Secondary Packaging), Scale of Operation (Clinical and Commercial) and Geography (North America, Europe, Asia Pacific and Rest of the World) , 2021-2030 report features an elaborate study of the current scenario and future opportunity within the cell therapy packaging products and services market. In addition, the report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. Amongst other elements, the report includes: An overview of the current market landscape of cell therapy packaging services providers, including a detailed analysis based on their year of establishment, company size, location of headquarters, package engineering design (primary and secondary), type of packaging (active and passive), packaging material (dry ice and liquid nitrogen), type of passive system used, temperature ranges supported, type of cells handled and additional services offered. A detailed assessment of the current market landscape of cell therapy packaging products, providing information on type of packaging container (bags, vials, shipping container and others), container fabrication material (plastic and others), storage temperature conditions, type of cells packed and usability of containers. In addition, the chapter highlights analysis of cell therapy packaging product provider(s), based on various parameters such as year of establishment, company size and location of headquarters and key players. An in-depth competitiveness analysis of cell therapy packaging service providers based in different geographies, by taking into consideration the service strength of a company (based on its experience), packaging portfolio (package engineering design, type of packaging, type of packaging material and temperature ranges supported) service portfolio (type of additional services offered) and company size (small, mid-sized and large companies). An analysis of the various partnerships established between cell therapy packaging providers and cell therapy developers, during the period, 2016-2021. It includes a brief description of various types of partnership models (namely service alliance, technology / platform integration agreement, merger and acquisition) adopted by stakeholders engaged in this domain. It is worth mentioning that the data captured during our research was analyzed based on several parameters, such as year of partnership, type of partnership, purpose of partnership, type of service covered and geographical location of players involved in a partnership. A list of more than 250 cell therapy developers anticipated to partner with cell therapy packaging providers, which have been shortlisted on the basis of developer strength (based on company size), type of therapy and pipeline maturity (based on stage of development of drug candidate). A case study highlighting the companies that claim to have the required expertise and capabilities for development and manufacturing of cell therapies, along with the information on their year of establishment, company size, location of headquarters and location of manufacturing facility. In addition, the chapter presents analysis on type of cells manufactured, source of cells, scale of operation and manufacturing capabilities / services of the aforementioned companies. Detailed profiles of the key players offering cell therapy packaging services and products. Each profile includes a brief overview of the company, details on cell therapy service portfolio, information on cell therapy packaging product portfolio, recent developments and an informed future outlook.

One of the key objectives of the report was to estimate the existing market size and future growth potential of the cell therapy packaging providers market. We have provided informed estimates on the likely evolution of the market in the short to mid-term and long term, for the period 2021-2030. Our year-wise projections of the current and future opportunity have further been segmented across [A] type of therapy (T-cell therapies, dendritic cell vaccines, stem cell therapies, NK cell therapies and other advanced therapy medicinal products), [B] package engineering design (primary and secondary packaging), [C] scale of operation (clinical and commercial) and [D] geography (North America, Europe, Asia Pacific and Rest of the World)

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

KEY QUESTIONS ANSWERED Who are the leading players offering cell therapy packaging services and products? What are the key considerations and challenges associated with cell therapy packaging? Which partnership models are commonly adopted by stakeholders engaged in this industry? Which players are likely to partner with cell therapy packaging service and product providers? What factors are likely to influence the evolution of the cell therapy packaging service providers market? What are the likely future trends in cell therapy packaging services market? How is the current and future opportunity likely to be distributed across key market segments?

RESEARCH METHODOLOGY The data presented in this report has been gathered via secondary research. For all our projects, we conduct interviews with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This information is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been validated from multiple sources of information.

The secondary sources of information include: Annual reports Investor presentations SEC filings Industry databases News releases from company websites Government policy documents Industry analysts views

While the focus has been on forecasting the market till 2030, the report also provides our independent views on various non-commercial trends emerging in this industry. The opinions are solely based on our knowledge, research and understanding of the relevant market trends gathered from various secondary sources of information.

CHAPTER OUTLINES Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the cell-based therapy manufacturing market and its likely evolution in the short to mid-term, and long term.

Chapter 3 provides a general introduction to the pharmaceutical filling and packaging, including information on types of pharmaceutical packaging. The chapter lays emphasis on cell therapy packaging, primary and secondary packaging of cell therapies. In addition, it discusses the key considerations and challenges associated with cell therapy packaging.

Chapter 4 features an overview of the current market landscape of cell therapy packaging services providers, including a detailed analysis on the year of establishment, company size and location of headquarters. In addition, the chapter highlights the analysis on the package engineering design (primary and secondary), type of packaging (active and passive), packaging material (dry ice and liquid nitrogen) and type of passive system used. Further, the chapter also presents analysis on temperature ranges supported, type of cells handled and additional services offered.

Chapter 5 fpresents a detailed assessment of the current market landscape of cell therapy packaging products, providing information on type of packaging container (bags, vials, shipping container and others), container fabrication material (plastic and others), storage temperature conditions, type of cells packed and usability of containers. In addition, the chapter highlights analysis of cell therapy packaging product provider(s), based on various parameters such as year of establishment, company size and location of headquarters and key players.

Chapter 6 includes profiles of the key players offering cell therapy packaging services and products. Each profile includes a brief overview of the company, details on cell therapy service portfolio, information on cell therapy packaging product portfolio, recent developments and an informed future outlook.

Chapter 7 presents in-depth competitiveness analysis of cell therapy packaging service providers based in different geographies, by taking into consideration the service strength of a company (based on its experience), packaging portfolio (package engineering design, type of packaging, type of packaging material and temperature ranges supported) service portfolio (type of additional services offered) and company size (small, mid-sized and large companies).

Chapter 8 provides an analysis of the various partnerships established between cell therapy packaging providers and cell therapy developers, during the period, 2016-2021. It includes a brief description of various types of partnership models (namely service alliance, technology / platform integration agreement, merger and acquisition) adopted by stakeholders engaged in this domain. It is worth mentioning that the data captured during our research was analyzed based on several parameters, such as year of partnership, type of partnership, purpose of partnership, type of service covered and geographical location of players involved in a partnership.

Chapter 9 presents a list of more than 250 cell therapy developers anticipated to partner with cell therapy packaging providers, which have been shortlisted on the basis of developer strength (based on company size), type of therapy and pipeline maturity (based on stage of development of drug candidate).

Chapter 10 features a case study highlighting the companies that claim to have the required expertise and capabilities for development and manufacturing of cell therapies, along with the information on their year of establishment, company size, location of headquarters and location of manufacturing facility. In addition, the chapter presents analysis on type of cells manufactured, source of cells, scale of operation and manufacturing capabilities / services of the aforementioned companies.

Chapter 11 presents a detailed market forecast analysis, providing insights on the likely growth of continuous manufacturing equipment providers market for the period 2021-2030. In addition, the chapter presents the likely distribution of the projected future opportunity based on type of therapy (T-cell therapies, dendritic cell vaccines, stem cell therapies, NK cell therapies and other advanced therapy medicinal products), package engineering design (primary and secondary packaging), scale of operation (clinical and commercial) and geography (North America, Europe, Asia Pacific and Rest of the World).

Chapter 12 is a summary of the overall report, which presents the insights on the contemporary market trends and the likely evolution of cell therapy products and services market.

Chapter 13 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix that provides the list of companies and organizations mentioned in the report.Read the full report: https://www.reportlinker.com/p06130493/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

See more here:
Cell Therapy Packaging Products and Services Market by Type - GlobeNewswire

Posted in Cell Therapy | Comments Off

Shoreline Launches into "Era of Cell Therapy" with $4 Billion in Partnerships – BioSpace

Posted: August 31, 2021 at 1:49 am

Shoreline Biosciences, an immunotherapy company formed in 2020 during the early days of the COVID-19 pandemic, was propelled into the proverbial catbirds seat this summer with two mega-deals, and now plans to double its employee base from 50 to 100 in the coming six to nine months.

Shoreline Biosciences is developing an off-the-shelf, targeted, allogeneic approach to natural killer (NK) and macrophage cell therapies, which Kleanthis G. Xanthopoulos, Ph.D., chairman and CEO, believes is one-of-a-kind.

This summers deals with Kite Pharmaceuticals, a Gilead Company, and BeiGene totaling $4 billion and boasting combined upfront payments of over $120 million to further develop its induced pluripotent stem cell (iPSC) programs are potent validation of Shorelines technology as well as its management. They go a long way toward ushering in what Xanthopoulos called the era of cell therapy.

Shorelines growing success is based on two pillars: solid science and experienced management.

You have to have the high science, but also enormous institutional know how, Xanthopoulos told BioSpace. These cells are finicky. There are significant challenges in manipulating them. Our founders have 20 years experience in this field.

BeiGene and Kite share our vision, and have extensive experience themselves BeiGene is incredible in protein engineering and Kite pioneered CAR T therapies, he said. So, when they chose to partner with Shoreline, they had performed competitive analysis and were saying, in essence, we believe in you and your capabilities.

These partnerships allow Shoreline to fast-forward its platforms.

For a company to bring so much capital and synergy to work is incredibly powerful, unique, and differentiated, Xanthopoulos said. It is difficult to find another early-stage preclinical company that has this kind of recognition and validation.

The new clinical data from Fate Therapeutics regarding its NK and T cell therapies help the field, too.

The science is very comprehensive, and we believe it will bring those programs forward, renewing interest in pluripotent stem cells and NK cells, Xanthopoulos surmised.

Shoreline Biosciences is developing off-the-shelf allogeneic therapies, bringing the benefit of stem cell therapies to many more patients than is possible with autologous transplants.

For autologous therapies, Xanthopoulos explains, It is costly to take patient cells, manipulate them in the lab, add guided chimeric antigen receptors, and return them to the patients There also are issues with rejection, as well as the more significant issues of cytokine release syndrome. Patients with aggressive tumors dont have the four to six weeks that method requires.

Shorelines allogeneic approach, therefore, creates targeted, off-the-shelf stem cell therapies.

The only effective way to do this is to start with pluripotent stem cells that can differentiate into more than 200 cell types, Xanthopoulos said. At Shoreline, we differentiate into hemopoietic cells. We are focused on NK cells and macrophages.

We have, basically, released the brakes for proliferating and activating the NK cells, he said, by editing out a negative regulator of activation and proliferation to create what essentially is a supercharged cell that is more metabolically fitted.

Preclinical studies in animals show the cells resist exhaustion, conferring a better pharmacokinetic profile and the need for fewer cytokines. Importantly, those efforts have been validated by independent researchers, in many published papers.

Results indicate the combination of pluripotent stem cells and NK cells results in a greater ability to kill various tumor cells using 5- to 10-fold less IL2 and IL15. Consequently, Xanthopoulos said, The overall therapy is less expensive.

Shoreline Biosciences plans to take this program into early human trials in the second half of 2022.

In 2023, we expect to file one or two Investigational New Drug (IND) applications, he said.

The benefit of an allogeneic iPSC approach to therapeutics development is clear.

You can perform a lot of genomic edits at the pluripotent state without a great many technical problems, he noted.

For example, transducing macrophages with chimeric antigen receptors (CAR) requires specialized vectors and results in low yields. But, if you start with pluripotent stem cells, you can make the modifications, isolate a single clone with the characteristics you want, and generate trillions of cells. With one patient dose requiring approximately 100 million cells, this method can lower the approximate $400,000 cost of therapy substantially.

To do this for NK cells, Shoreline Biosciences created a unique, powerful engine and then determined how to decorate the resulting cells. After considering such issues as cell signaling, targeting, and toxicity, Xanthopoulos said, We engineered what you can think of as hooks where antibodies recognize and interact tightly, for higher killing activity.

As Xanthopoulos, a serial entrepreneur who has founded and operated four previous biotech companies, told BioSpace, Ive never been more excited. Stem cell therapies are proven. They are the next frontier of medicine.

They arent in the distant future, either. I think the era of cell therapies is here and now, and will dominate the landscape going forward. If we learn to make less immunogenic therapies, stem cell therapeutics will continue to increase momentum.

As Shoreline looks to the future, it is building an expansive team and is continuing to hire in all categories. We plan to double to about 100 employees in the next six to nine months, and have several outstanding investors onboard.

Excerpt from:
Shoreline Launches into "Era of Cell Therapy" with $4 Billion in Partnerships - BioSpace

Posted in Cell Therapy | Comments Off

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma – DocWire News

Posted: August 31, 2021 at 1:49 am

This article was originally published here

Ann Med. 2021 Dec;53(1):1547-1559. doi: 10.1080/07853890.2021.1970218.

ABSTRACT

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy shows impressive results in clinical trials. We conducted a meta-analysis based on the most recent data to systematically describe the efficacy and safety of anti-BCMA CAR T therapy for patients with relapsed or refractory multiple myeloma (R/R MM).

METHODS: PubMed, Embase, Web of Science, Cochrane library, ClinicalTrials.gov, China Biology Medicine disc (CBM disc) and Wanfang Data were searched on 8 November 2020. Registration number of PROSPERO was CRD42020219127.

RESULTS: From 763 articles, we identified 22 appropriate studies with 681 patients. The pooled overall response rate (ORR) was 85.2% (95%CI 0.797-0.910), complete response rate (CRR) was 47.0% (95%CI 0.378-0.583), and minimal residual disease (MRD) negativity rate was 97.8% (95%CI 0.935-1.022). The pooled incidence of grade 3-4 cytokine release syndrome was 6.6% (95%CI 0.036-0.096) and neurotoxicity was 2.2% (95%CI 0.006-0.038). The median progression-free survival (PFS) was 14.0 months and median overall survival (OS) was 24.0 months. Subgroup analysis showed dual epitope-binding CAR T cells achieved the best therapy outcomes and humanized CAR T cells had the best safety profile. Patients who were older, heavily pre-treated or received lower dose of CAR T cells had worse ORR. There was no significant difference in ORR, CRR and PFS between patients with and without high-risk cytogenetic features. The PFS and CRR of non-extramedullary disease (EMD) group was superior to those of EMD group.

CONCLUSION: Anti-BCMA CAR T therapy is effective and safe for patients with R/R MM. It can improve the prognosis of patients with high-risk cytogenetic features while the prognosis of patients with EMD remains poor. Moreover, patients are likely to benefit from an earlier use of CAR T therapy and human-derived CAR T cells have obvious advantages based on the existing data.

PMID:34459681 | DOI:10.1080/07853890.2021.1970218

Read the original:
Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma - DocWire News

Posted in Cell Therapy | Comments Off

Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate Clinical Trial of Ovarian Cancer CAR-T Immunotherapy – Yahoo Finance

Posted: August 31, 2021 at 1:49 am

SAN JOSE, Calif., Aug. 30, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its CAR-T (Chimeric Antigen Receptor-T cell) therapy, which is being developed in partnership with Moffitt Cancer Center (Moffitt).

Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)

Dr. Robert Wenham, Chair of Gynecological Oncology at Moffitt will lead the clinical trial.

This CAR-T therapy was developed by Dr. Jose Conejo-Garcia and his research team, when he was at the Wistar Institute. Dr. Conejo-Garcia is currently the Chairman of Immunology at Moffitt.

Anixa Biosciences has an exclusive worldwide license to the technology.

This technology is an autologous cell therapy. The therapeutic product is comprised of engineered T-cells that target the follicle stimulating hormone receptor (FSHR). FSHR is found at immunologically relevant levels exclusively on the granulosa cells of the ovaries. Since the target is a hormone receptor, and the target-binding domain is derived from its natural ligand, this technology is also known as CER-T (Chimeric Endocrine Receptor T-cell) therapy, a new type of CAR-T.

Dr. Amit Kumar, President and CEO of Anixa stated, "We are pleased that the FDA has authorized us to commence human clinical trials of our potentially paradigm-shifting therapy. Outcomes for women with late-stage ovarian cancer are poor, so if this approach demonstrates efficacy, it would have a dramatic impact on patients for whom there are no other options."

"This is a major milestone for our program. CAR-T therapy has had major successes in B-cell malignancies, but no clinical success in other types of tumors. We feel that our technology could be the first CAR-T approach that will demonstrate efficacy in a solid tumor indication, and we are looking forward to testing and verifying that assertion in human trials," said Dr. Wenham.

Story continues

In addition to Drs. Wenham and Conejo-Garcia, other key members of the team at Moffitt include:

Dr. Marco Davila, Clinician and Director of the Cell Therapy Facility at Moffitt

Dr. Daniel Abate Daga, Assistant Director of the Cell Therapy Facility at Moffitt

Dr. Ana Marie Landin, Experimental Cell Therapy Manager at Moffitt

Dr. Theresa Boyle, Department of Pathology at Moffitt

Carrie Thomas, FDA Regulatory Liaison at Moffitt

Tam Jackson, Project Management Consultant

Scientists and Members of the Moffitt Cell Therapy Facility

Members of the Moffitt Alliance Relations Team

About Anixa Biosciences, Inc.Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. The company's vaccine portfolio includes a vaccine to prevent breast cancer, and specifically triple negative breast cancer (TNBC), the most deadly form of the disease, and a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against specific proteins that have been found to be expressed in certain forms of cancer. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Additional information is available at http://www.anixa.com.

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:Mike Catelanimcatelani@anixa.com408-708-9808

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-and-moffitt-cancer-center-announce-fda-clearance-to-initiate-clinical-trial-of-ovarian-cancer-car-t-immunotherapy-301364747.html

SOURCE Anixa Biosciences, Inc.

More:
Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate Clinical Trial of Ovarian Cancer CAR-T Immunotherapy - Yahoo Finance

Posted in Cell Therapy | Comments Off

Monthly Archives: August 2021

The Bat Elixir: Geneticists Suspect that the Flying Mammal Holds the Key to Extended Healthy Life | The Weather Channel – Articles from The Weather…

Roslin Tech in multi-million bid to fund sustainable food – HeraldScotland

25 Fad Diets That Did Not Stand the Test of Time – Parade Magazine

Scope of Endocrine Testing Market Size, Status and Top Key Vendors (Abbott, Agilent, Bio Rad, Roche, Quest Diagnostics, QIAGEN) | Forecast to 2028 …

BioCure Technology to Develop ROR1-Targeted CAR-T Cell Therapy – Precision Oncology News

A Phase I Study of FT819 CAR T-Cell Therapy in People with B-Cell Cancers – On Cancer – Memorial Sloan Kettering

Cell Therapy Packaging Products and Services Market by Type – GlobeNewswire

Shoreline Launches into "Era of Cell Therapy" with $4 Billion in Partnerships – BioSpace

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma – DocWire News

Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate Clinical Trial of Ovarian Cancer CAR-T Immunotherapy – Yahoo Finance

Categories

Archives

Recommended Sites

Contact Us

Recent Posts